MLH1/PMS2 Inhibitor Compounds for Mismatch Repair Modulation

The patent segments the treatment approach by developing specific small molecule compounds that independently target MLH1 and PMS2 proteins. These compounds can be used as monotherapy or combined with immunotherapy agents, creating distinct treatment segments for different clinical scenarios. The segmentation allows for targeted inhibition of mismatch repair proteins without requiring broad-spectrum approaches.

The patent creates multi-functional treatment strategies where the same MLH1/PMS2 inhibitors can be applied across different cancer types with mismatch repair deficiency (Lynch syndrome, constitutional mismatch repair deficiency syndrome, sporadic cancers). The compounds serve multiple functions: direct cytotoxic effect on tumor cells, modulation of immune response, and potential combination with various immunotherapy agents, providing universal applicability across different clinical contexts.

The patent uses small molecule compounds as intermediaries that bridge the gap between direct protein inhibition and immune system activation. These compounds first bind to and inhibit MLH1/PMS2 proteins, which then triggers downstream effects including increased tumor mutational burden and enhanced immune recognition. The intermediary compounds simplify the overall mechanism by providing a single point of intervention that cascades into multiple beneficial effects.

The patent employs preliminary inhibition of MLH1/PMS2 activity to prepare the tumor microenvironment for subsequent immune therapy. By pre-treating with MLH1/PMS2 inhibitors, the tumor accumulates more mutations and becomes more immunogenic before immunotherapy is administered, thereby enhancing the overall efficacy of the treatment sequence.

The patent achieves local quality by designing compounds with high specificity for MLH1 and PMS2 proteins. The small molecule inhibitors are structurally optimized to bind selectively to the active sites of these specific mismatch repair proteins while minimizing interaction with other cellular targets. This selective binding ensures that the mutagenic effects are localized primarily to the intended molecular targets, reducing off-target toxicity.

The patent employs structure-based drug design where compounds are created as molecular copies or analogs of natural substrates that naturally bind to MLH1/PMS2. By copying the binding interface of endogenous ligands, the inhibitors achieve high specificity for the target proteins, ensuring that only the intended molecular interactions are disrupted while sparing other cellular processes.